Antisense molecules for targeted cancer therapy

Wacheck, V; Zangemeister-Wittke, Uwe (2006). Antisense molecules for targeted cancer therapy. Critical reviews in oncology, hematology, 59(1), pp. 65-73. Boca Raton, Fla.: Elsevier 10.1016/j.critrevonc.2005.10.004

Full text not available from this repository. (Request a copy)

The efficacy of traditional anti-cancer agents is hampered by toxicity to normal tissues, due to the lack of specificity for malignant cells. Recent advances in our understanding of molecular genetics and tumor biology have led to the identification of signaling pathways and their regulators implicated in tumorigenesis and malignant progression. Consequently, novel biological agents were designed which specifically target key regulators of cell survival and proliferation activated in malignant cells and thus are superior to unspecific cytotoxic agents. Antisense molecules comprising conventional single-stranded antisense oligonucleotides (ASO) and small interfering RNA (siRNA) inhibit gene expression on the transcript level. Thus, they specifically target the genetic basis of cancer and are particularly useful for inhibiting the expression of oncogenes the protein products of which are inaccessible to small molecules or inhibitory antibodies. Despite the somewhat disappointing results of recent antisense oncology trials, the identification of new cancer targets and ongoing progress in ASO and siRNA technology together with improvements in tumor targeted delivery have raised new hopes that this fascinating intervention concept will eventually translate into enhanced clinical efficacy.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology

UniBE Contributor:

Zangemeister-Wittke, Uwe

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1040-8428

ISBN:

16750913

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:48

Last Modified:

26 Jul 2018 16:02

Publisher DOI:

10.1016/j.critrevonc.2005.10.004

PubMed ID:

16750913

Web of Science ID:

000238868700006

URI:

https://boris.unibe.ch/id/eprint/20242 (FactScience: 3429)

Actions (login required)

Edit item Edit item
Provide Feedback